• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Immunology, endocrine & metabolic agents in medicinal chemistry. >Surrogate Outcomes for Progression in the Initial Stages of Diabetic Retinopathy
【24h】

Surrogate Outcomes for Progression in the Initial Stages of Diabetic Retinopathy

机译：糖尿病视网膜病变初期的替代结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diabetic retinopathy remains the most frequent cause of new cases of blindness among adults aged 20-74 years. A number of large trials have validated that laser photocoagulation is a useful treatment but the disease continues to progress in approximately 50% of eyes treated by photocoagulation.Current treatment of diabetic retinopathy is only available for advanced stages of the disease and is given independently of the diabetes disease status itself and metabolic status. Other forms of therapy targeted at the earliest stages of retinal disease are needed.Proposals for defining and accepting surrogate outcomes that appropriately evaluate the earlier stages of the retinopathy are presented in this review. The most likely candidates for surrogate outcomes are: mean difference in ETDRS retinopathy scale, 2 steps per eye, microaneurysm turnover and reduction in macular thickening.
机译：在20-74岁的成年人中，糖尿病性视网膜病仍然是导致新的失明病例的最常见原因。许多大型试验已证实激光光凝是一种有用的治疗方法，但在约50％的光凝治疗眼中，该疾病仍在继续发展。目前，糖尿病性视网膜病的治疗仅适用于该病的晚期阶段，且与糖尿病视网膜病变无关糖尿病本身的疾病状态和代谢状态。还需要针对视网膜疾病早期阶段的其他形式的治疗方法。本综述提出了定义和接受替代结果以适当评估视网膜病变早期阶段的建议。替代结果最可能的候选者是：ETDRS视网膜病变量表的平均差异，每只眼睛2步，微动脉瘤周转和黄斑增厚的减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号